Nanocrystals: Production, Cellular Drug Delivery, Current and Future Products - Intracellular Delivery: Fundamentals and Applications - page 430

appeared on the market. From our point of view, the nanocrystals have clear
advantages compared to many of the “academic” nanocarriers presently under
development. These are besides others accepted status of excipients, well tolerable
(NCS class I/III), easy and cost-effective large scale production, proven make-ability
of products. Tricor ® is the first nano block buster, making the nanocrystals to the
most successful nanotechnology by now.
The next steps will be to combine sophisticated targeting approaches with the
nanocrystals as carrier and to exploit much more the opportunities in controlled
intracellular delivery.
Acknowledgement The authors thank Abbott GmbH und Ko. KG and its drug delivery company
Soliqs/Ludwigshafen in Germany for the kind permission to reproduce the NanoMorph picture in
Fig. 1 , right.
References
Alyautdin R, Gothier, D., Petrov, V., Kharkevich, D., Kreuter, J. (1995) Analgesic activity of the
hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacry-
late) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 41:44-48
Auweter H, Bohn H, Heger R, Horn D, Siegel B, Siemensmeyer K (2002) Precipitated water-
insoluble colorants in colloid disperse form. United States Patent 6,494,924
Bénet N, Muhr H, Plasari E, Rousseaux JM (2002) New technologies for the precipitation of solid
particles with controlled properties. Powder Technology 128 (2-3):93-98
Blunk T, Hochstrasser DF, Sanchez JC, Müller BW, Müller RH (1993) Colloidal carriers for
intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex
particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14
(12):1382-1387
Böhm BHL (1999) Herstellung und Charakterisierung von Nanosuspensionen als neue Arzneiform
für Arzneistoffe mit geringer Bioverfügbarkeit. PhD-thesis, Freie Universität Berlin,
Böhm BHL, Behnke D, Müller RH Production of paclitaxel nanosuspensions by high-pressure
homogenisation. In: Int. Symp. Control. Rel. Bioact. Mater. 24, 1997. pp 927-928
Buckton G, Beezer AE (1992) The relationship between particle size and solubility. International
Journal of Pharmaceutics 82 (3):R7-R10
Byrappa K, Ohara S, Adschiri T (2008) Nanoparticles synthesis using supercritical fluid technol-
ogy - towards biomedical applications. Advanced Drug Delivery Reviews 60 (3):299-327
Chen J-F, Wang Y-H, Guo F, Wang X-M, Zheng C (2009) Synthesis of Nanoparticles with Novel
Technology: High-Gravity Reactive Precipitation. Industrial & Engineering Chemistry
Research 39 (4):948-954
Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B,
Gendelman HE (2009) Macrophage delivery of nanoformulated antiretroviral drug to the brain
in a murine model of neuroAIDS. J Immunol 183 (1):661-669
Dye D, Watkins J (1980) Suspected anaphylactic reaction to Cremophor EL. Br Med J 280
(6228):1353
Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W (2008) Studies on pharmacokinetics
and tissue distribution of oridonin nanosuspensions. Int J Pharm 355 (1-2):321-327
Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B,
Zanella FE, Kreuter J (2002) Toxicological studies of doxorubicin bound to polysorbate
80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial
glioblastoma. Toxicology Letters 126 (2):131-141